Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after viral eradication: A nationwide registry study in Taiwan
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Steatotic liver disease (SLD) is a common manifestation in chronic hepatitis C (CHC). Metabolic alterations in CHC are associated with metabolic dysfunction-associated steatotic liver disease (MASLD). We aimed to elucidate whether hepatitis C virus (HCV) eradication mitigates MASLD occurrence or resolution. Methods: We enrolled 5,840 CHC patients whose HCV was eradicated by direct-acting antivirals in a nationwide HCV registry. MASLD and the associated cardiometabolic risk factors (CMRFs) were evaluated at baseline and 6 months after HCV cure. Results: There were 2,147 (36.8%) patients with SLD, and 1,986 (34.0%) of them met the MASLD criteria before treatment. After treatment, HbA1c (6.0% vs. 5.9%, P<0.001) and BMI (24.8 kg/m2 vs. 24.7 kg/m2, P<0.001) decreased, whereas HDL-C (49.1 mg/dL vs. 51.9 mg/dL, P<0.001) and triglycerides (102.8 mg/dL vs. 111.9 mg/dL, P<0.001) increased significantly. The proportion of patients with SLD was 37.5% after HCV eradication, which did not change significantly compared with the pretreatment status. The percentage of the patients who had post-treatment MASLD was 34.8%, which did not differ significantly from the pretreatment status (P=0.17). Body mass index (BMI) (odds ratio [OR] 0.89; 95% confidence intervals [CI] 0.85–0.92; P<0.001) was the only factor associated with MASLD resolution. In contrast, unfavorable CMRFs, including BMI (OR 1.10; 95% CI 1.06–1.14; P<0.001) and HbA1c (OR 1.19; 95% CI 1.04–1.35; P=0.01), were independently associated with MASLD development after HCV cure. Conclusions: HCV eradication mitigates MASLD in CHC patients. CMRF surveillance is mandatory for CHC patients with metabolic alterations, which are altered after HCV eradication and predict the evolution of MASLD.
Abstract
Background/Aims: Steatotic liver disease (SLD) is a common manifestation in chronic hepatitis C (CHC). Metabolic alterations in CHC are associated with metabolic dysfunction-associated steatotic liver disease (MASLD). We aimed to elucidate whether hepatitis C virus (HCV) eradication mitigates MASLD occurrence or resolution. Methods: We enrolled 5,840 CHC patients whose HCV was eradicated by direct-acting antivirals in a nationwide HCV registry. MASLD and the associated cardiometabolic risk factors (CMRFs) were evaluated at baseline and 6 months after HCV cure. Results: There were 2,147 (36.8%) patients with SLD, and 1,986 (34.0%) of them met the MASLD criteria before treatment. After treatment, HbA1c (6.0% vs. 5.9%, P<0.001) and BMI (24.8 kg/m2 vs. 24.7 kg/m2, P<0.001) decreased, whereas HDL-C (49.1 mg/dL vs. 51.9 mg/dL, P<0.001) and triglycerides (102.8 mg/dL vs. 111.9 mg/dL, P<0.001) increased significantly. The proportion of patients with SLD was 37.5% after HCV eradication, which did not change significantly compared with the pretreatment status. The percentage of the patients who had post-treatment MASLD was 34.8%, which did not differ significantly from the pretreatment status (P=0.17). Body mass index (BMI) (odds ratio [OR] 0.89; 95% confidence intervals [CI] 0.85–0.92; P<0.001) was the only factor associated with MASLD resolution. In contrast, unfavorable CMRFs, including BMI (OR 1.10; 95% CI 1.06–1.14; P<0.001) and HbA1c (OR 1.19; 95% CI 1.04–1.35; P=0.01), were independently associated with MASLD development after HCV cure. Conclusions: HCV eradication mitigates MASLD in CHC patients. CMRF surveillance is mandatory for CHC patients with metabolic alterations, which are altered after HCV eradication and predict the evolution of MASLD.
참고문헌 (31)
- Huang CF, "PNPLA3 genetic variants determine hepatic steatosis in non-obese chronic hepatitis C patients", Sci Rep, 5, pp.11901~ (2015)
- Lonardo A, "Steatosis and hepatitis C virus : mechanisms and significance for hepatic and extrahepatic disease", Gastroenterology, 126, pp.586~597 (2004)
- Younossi Z, "Global burden of NAFLD and NASH : trends, predictions, risk factors and prevention", Nat Rev Gastroenterol Hepatol, 15, pp.11~20 (2018)
- Siphepho PY, "The impact of steatosis on chronic hepatitis C progression and response to antiviral treatments", Biomedicines, 9, pp.1491~ (2021)
- Huang JF, "The outcomes of glucose abnormalities in chronic hepatitis C patients receiving interferon-free direct antiviral agents", Kaohsiung J Med Sci, 33, pp.567~571 (2017)
- Jang TY, "Amelioration of glucose intolerance through directly acting antiviral agents in chronic hepatitis C cirrhotic patients without overt diabetes", Kaohsiung J Med Sci, 38, pp.897~906 (2022)
- Huang CF, "Cure or curd : modification of lipid profiles and cardio-cerebrovascular events after hepatitis C virus eradication", Kaohsiung J Med Sci, 36, pp.920~928 (2020)
- Cespiati A, "Effect of HCV eradication by DAAs on liver steatosis, carotid atherosclerosis, and associated metabolic comorbidities : a systematic review", Liver Int, 44, pp.1075~1092 (2024)
- Rinella ME, "A multisociety Delphi consensus statement on new fatty liver disease nomenclature", J Hepatol, 79, pp.1542~1556 (2023)
- Rinella ME, "A multisociety Delphi consensus statement on new fatty liver disease nomenclature", Hepatology, 78, pp.1966~1986 (2023)
- Huang CF, "Chronic hepatitis C related steatotic liver disease is more than"miscellaneous steatotic liver disease"", Clin Gastroenterol Hepatol, pp.S1542-3565(24)00430-0~ (2024)
- Yu ML, "An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from Taiwan", Hepatol Int, 18, pp.461~475 (2024)
- Huang CF, "Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan", Sci Rep, 11, pp.23473~ (2021)
- Huang CF, "Impact of sofosbuvir-based direct-acting antivirals on renal function in chronic hepatitis C patients with impaired renal function : a large cohort study from the nationwide HCV registry program(TACR)", Clin Gastroenterol Hepatol, 20, pp.1151~1162 (2022)
- Sharma P, "Effect of COVID-19 on pre-existing liver disease : what hepatologist should know?", J Clin Exp Hepatol, 11, pp.484~493 (2021)
- Huang JF, "Updates in the management and treatment of HCV genotype 3, what are the remaining challenges?", Expert Rev Anti Infect Ther, 16, pp.907~912 (2018)
- Oliveira C, "Apolipoprotein(a)inhibits hepatitis C virus entry through interaction with infectious particles", Hepatology, 65, pp.1851~1864 (2017)
- Agnello V, "Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor", Proc Natl Acad Sci U S A, 96, pp.12766~12771 (1999)
- Huang JF, "Pegylated interferon plus ribavirin therapy improves pancreatic β-cell function in chronic hepatitis C patients", Liver Int, 31, pp.1155~1162 (2011)
- Wang CW, "Hepatitis C virus infection associated with coronary and thoracic aortic atherosclerosis", Am J Med Sci, 368, pp.203~213 (2024)
- Su X, "Antiviral treatment for hepatitis C is associated with a reduced risk of atherosclerotic cardiovascular outcomes : a systematic review and meta-analysis", J Viral Hepat, 28, pp.664~671 (2021)
- Lee MH, "Chronic viral hepatitis B and C outweigh MASLD in the associated risk of cirrhosis and HCC", Clin Gastroenterol Hepatol, 22, pp.1275~1285 (2024)
- Yen YH, "The association between steatosis and diabetes with hepatocellular carcinoma in non-genotype 3 chronic hepatitis C patients", Liver Int, 38, pp.1064~1073 (2018)
- Sano T, "Metabolic management after sustained virologic response in elderly patients with hepatitis C virus : a multicenter study", Hepatol Res, 54, pp.326~335 (2024)
- Rout G, "Therapy with oral directly acting agents in hepatitis C infection is associated with reduction in fibrosis and increase in hepatic steatosis on transient elastography", J Clin Exp Hepatol, 9, pp.207~214 (2019)
- Trifan A, "Changes in liver steatosis using controlled attenuation parameter among patients with chronic hepatitis C infection treated with direct-acting antivirals therapy who achieved sustained virological response", Diagnostics(Basel), 12, pp.702~ (2022)
- Tokuchi Y, "Hepatitis C virus eradication by direct-acting antivirals causes a simultaneous increase in the prevalence of fatty liver and hyper low-density lipoprotein cholesterolemia without an increase in body weight", Hepatol Res, 53, pp.595~606 (2023)
- Tada T, "Viral eradication reduces both liver stiffness and steatosis in patients with chronic hepatitis C virus infection who received direct-acting anti-viral therapy", Aliment Pharmacol Ther, 47, pp.1012~1022 (2018)
- Kobayashi N, "Changes in liver stiffness and steatosis among patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response", Eur J Gastroenterol Hepatol, 30, pp.546~551 (2018)
- Shimizu K, "Eradication of hepatitis C virus is associated with the attenuation of steatosis as evaluated using a controlled attenuation parameter", Sci Rep, 8, pp.7845~ (2018)
- Cespiati A, "Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by directacting antiviral therapy(DAAs) : evaluation by the controlled attenuation parameter(CAP)", Dig Liver Dis, 53, pp.1301~1307 (2021)